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Histone deacetylases (HDACs), enzymes in-
volved in chromatin remodeling, are promising
targets for anticancer drug development. Sev-
eral HDAC inhibitors (HDACi) are in clinical trials.
One limitation of present HDACi is their non-
specificity, affecting many HDACs with similar
effectiveness. We have identified a small mole-
cule, the sesquiterpene lactone parthenolide
(PN), which specifically depletes HDAC1 pro-
tein without affecting other class I/II HDACs.
HDAC1 depletion occurred through proteaso-
mal degradation and resulted in transcriptional
consequences comparable to those observed
with pan-HDACi. Surprisingly, HDAC1 depletion
did not occur through the inflammation media-
tor IKK2, a known PN target and regulator of
HDAC1. Rather, PN promotedHDAC1 depletion
and cell death through the DNA-damage-
transducer ataxia telangiectasia mutated. Our
study suggests that modulating cellular HDAC
protein levels with small molecules provides
an alternative approach to specificHDAC inhibi-
tion and effective cancer treatment.
INTRODUCTION
Histone deacetylases (HDACs) are enzymes that catalyze
the removal of acetyl groups from acetyllysine residues in
proteins. Researchers have identified 18 human HDACs
that are grouped into four classes based on their se-
quence homology [1, 2]. HDACs were originally identified
as epigenetic regulators of gene expression that deacety-
late histone H3 and histone H4 N-terminal tails and
promote transcriptionally silent chromatin [3]. However,
HDACs also catalyze the deacetylation of many nonhis-
tone proteins like p53, signal transducer and activator
of transcription 3, nuclear factor-kB (NF-kB), Bax, and
hypoxia-inducible factor 1, thereby regulating their activi-
ties through changes in their stability, protein-protein
interactions, and subcellular localization [4, 5].Chemistry & Biology 14,Studies over the past decade have consistently indi-
cated that several HDACs play important roles in promot-
ing oncogenesis. Foremost is HDAC1, which is overex-
pressed in several cancers and is a critical transcriptional
repressor of the cyclin-dependent kinase inhibitors
p21WAF1/CIP1 and p27KIP1, which normally suppress cell
proliferation [6, 7]. This has spurred the development of
several HDAC inhibitors (HDACi), some of which have
shown impressive pharmacological properties and are in
the final stages of clinical development [4, 8]. However,
most all HDACi are pan-HDAC inhibitors, enzymatically
inhibiting class I, II, and IV HDACs with comparable effi-
ciency. The inhibition of multiple HDACs can have unde-
sirable consequences; thus the search for more specific
HDACi remains an ongoing pursuit.
The activity of HDACs is regulated atmany levels [9]. For
example, the class I HDACs HDAC1, HDAC2, and HDAC3
are known to be associated with multiprotein complexes
Sin3, NuRD, and SMRT/N-CoR, and it is through these
complexes that HDACs are both enzymatically active
and functionally competent to recognize their appropriate
substrates [10–12]. HDAC activity can also be regulated
both positively and negatively by post-translational modi-
fications, including phosphorylation and sumoylation.
These modifications can affect HDAC association with
multiprotein complexes, as is the case with HDAC1 C-
terminal phosphorylation and its association with the
Sin3 complex, or the subcellular localization of HDAC pro-
teins, as is the case with N-terminal phosphorylation of
class II HDACs 4, 5, 7, and 9 and their cytoplasmic local-
ization promoted by 14-3-3 binding [13, 14]. HDACs can
be transcriptionally autoregulatory (e.g., HDAC1) or cross-
regulatory (e.g., HDAC1 affecting HDACs 2 and 3), and
splice variants exist for class II HDACs 3 and 9 and the
class IV HDAC11 [7, 15–17]. In addition, all class III
HDACs, otherwise known as sirtuins, are completely de-
pendent on the cofactor NAD+, and regulating NAD+ levels
or the levels of competitive inhibitors NADH and nicotin-
amide can affect class III HDAC function [18].
Previously, we had found that the proinflammatory
agents such as the cytokine tumor necrosis factor-
a (TNF-a) induced ubiquitination-mediated proteasomal
degradation of HDAC1 through activated IkB kinase 2
(IKK2) [19]. HDAC1 depletion by TNF-a caused a decrease
in HDACs 1 and 2 associated with the p21 promoter, in-
creased local and global histone H3 acetylation, and813–823, July 2007 ª2007 Elsevier Ltd All rights reserved 813
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occur following treatment with pan-HDACi. Notably, the
depletion caused by TNF-a treatment was specific for
HDAC1 and speaks to the importance of this HDAC in reg-
ulating the expression of many genes.
While investigating small-molecule inhibitors of TNFa-
mediated HDAC1 depletion, we unexpectedly discovered
that the IKK2 inhibitor parthenolide (PN) (Figure 1) itself did
not inhibit but, instead, promoted HDAC1 depletion. PN is
the primary bioactive agent in feverfew, a traditional herbal
medicine used for the treatment of fever, migraines, arthri-
tis, and superficial inflammation [20]. Structure-function
relationship studies have indicated that the epoxide and
a-methylene-g-lactone moieties of this sesquiterpene
lactone compound are responsible for its activity, which
allows PN to readily react with nucleophilic sites on biolog-
ical molecules such as exposed cysteines, thereby inacti-
vating critical proteins [21]. Mechanistically, the anti-
inflammatory effects of PN are thought to stem from its
inhibition of canonical p65RELA/p50 NF-kB activation by
the IKK signalsome, through direct interaction of PN with
IKK2 [22, 23]. However, PN has also been shown to pro-
mote apoptosis of cancer cells through additional mecha-
nisms, including increasing intracellular concentrations of
reactive oxygen species (ROS) and sustained activation of
the c-Jun N-terminal kinase (JNK) [24–26]. In addition,
while its exact mechanism is unknown, PN is the only re-
ported small molecule demonstrating selective toxicity
against cancer stem cells [27]. Here, we report that PN
specifically depletes HDAC1 through ubiquitination and
proteasomal degradation by activating the signal trans-
ducer protein ataxia telangiectasia mutated (ATM) inde-
pendent of IKK2 and JNK1/2.
RESULTS
PN Specifically Depletes HDAC1 through
Proteasomal Degradation
PN is a known inhibitor of IKK2 [23], and IKK2 activity is re-
quired for TNFa-mediated HDAC1 depletion [19]. Thus, it
was quite unexpected when we discovered that PN
treatment alone actually depleted HDAC1 protein from
ZR-75-1 human breast carcinoma cells in a time- and
concentration-dependent manner (Figures 2A and 2B).
We observed a similar HDAC1 depletion in many PN-
treated cancer cells and transformed cells of different lin-
eages (see Figure S1 in the Supplemental Data available
with this article online). This depletion was specific for
HDAC1 as we found no observable changes in the protein
levels or cytoplasmic/nuclear distribution of the other
class I and class II HDAC proteins tested (Figures 2A
and 2B). HDAC1 depletion was also reversible, with
HDAC1 levels returning to normal 24 hr after PN treatment
(Figure 2C). It should be noted that these changes in
HDAC1 protein levels occurred with PN concentrations
and cell exposure times comparable to those routinely
used to explore the biological effects of PN [21–26].
HDAC1 is primarily a nuclear protein [2]. However, its de-
pletion following PN treatment did not result froma change814 Chemistry & Biology 14, 813–823, July 2007 ª2007 Elseviein its subcellular localization (Figures 2A and 2B), nor from
its sequestration into an insoluble fraction (Figure 2D). A
real-time quantitative reverse transcription (RT)-polymer-
ase chain reaction (PCR) assay did not reveal any reduc-
tions in HDAC1 mRNA levels (Figure 2E), suggesting that
changes in transcription of the HDAC1 gene or stability
of HDAC1 mRNA were not responsible for PN-mediated
HDAC1 depletion. Similarly, HDAC1 depletion was likely
not the result of PN-mediated inhibition of HDAC1 deace-
tylase activity, because loss of HDAC1 activity correlated
directly with loss of HDAC1 protein (Figure 2F). In fact,
we observed no inhibition of deacetylase activity following
direct PN treatment of immunoprecipitated HDAC1 (Fig-
ure 2F). However, treatment with the proteasomal inhibitor
MG-132 but not the pan-caspase inhibitor Z-VAD-FMK
blocked the depletion of HDAC1 (Figure 2G), suggesting
that ubiquitination and proteasomal degradation are re-
sponsible for PN-mediated HDAC1 depletion. This was
confirmed through immunoprecipitation experiments,
where MG-132-treated cells were found to contain greatly
increased quantities of slower mobility, ubiquitinated
HDAC1 protein (Figure 2H). In addition, previous studies
have found that lysine residues within the C-terminal
region of HDAC1 (amino acids 432–482) may be
Figure 1. Chemical Structures of Parthenolide, PN, and Ki-
nase Inhibitors Used in This Studyr Ltd All rights reserved
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Parthenolide Depletes HDAC1 through ATMFigure 2. PN Specifically Depletes HDAC1 Protein through Ubiquitination and Proteasomal Degradation
(A) Western blots of cytoplasmic and nuclear extract proteins from ZR-75-1 cells treatedwith PN at increasing concentrations for 3 hr and probedwith
the indicated antibodies (right). Paxillin andpoly(ADP-ribose) polymerase (PARP) blots served as protein-loading controls and as controls for cytoplas-
mic and nuclear extract integrity.
(B) Western blots performed as described in (A) but with 15 mM PN and increasing treatment durations.
(C) Western blots of nuclear extract proteins from ZR-75-1 cells treated with 15 mM PN for extended durations.
(D) Western blots of Laemmli loading buffer-extractable proteins from ZR-75-1 cells treated with 15 mM PN for the times indicated.
(E) HDAC1mRNA levels in ZR-75-1 cells treatedwith 15 mMPNas determined using a real-time quantitative RT-PCRassay after normalization against
glyceraldehyde-3-phosphate dehydrogenase mRNA levels. Error bars indicate standard error of the mean.
(F)Western blots ofHDAC1protein immunoprecipitatedwith anti-HDAC1antibodies fromZR-75-1 cells treatedwith 15mMPN for increasing durations
(PN/IP) or immunoprecipitated from untreated ZR-75-1 cells and then treated with 15 mM PN for increasing durations in vitro (IP/PN) (top panel).
Histone deacetylase activity measurements of HDAC-1 protein immunoprecipitated from PN-treated ZR-75-1 cells (PN/IP, red triangles) or immu-
noprecipitated HDAC1 from untreated ZR-75-1 cells subsequently treated with PN in vitro (IP/PN, inverted blue triangles) (bottom panel). Error bars
indicate standard error of the mean.
(G)Western blots of whole cell extract proteins fromZR-75-1 cells treated for 3 hr with 10 mMMG-132, 10 mMZ-VAD-FMK, and 15 mMPNas indicated.
(H) Western blots of HDAC1 protein immunoprecipitated from ZR-75-1 cells treated with 15 mM PN and/or 10 mMMG-132 for 3 hr, as indicated, and
probed with ubiquitin antibodies (top panel) or stripped and reprobed with HDAC1 antibodies (bottom panel).
(I) Schematic representation of HDAC1 protein illustrating its histone deacetylase domain (amino acids 10–321, light gray) and lysine-rich carboxy ter-
minus (amino acids 432–482, dark gray) (top panel). Western blots of nuclear extract proteins from 293T cells expressing theC-terminal FLAGepitope-
tagged mutant HDAC1 proteins indicated following treatment of these cells with or without 15 mM PN for 3 hr as indicated.post-translationally modified with ubiquitin and SUMO-1
(small ubiquitin-related modifier) [28]. Using plasmid vec-
tors expressing HDAC1 mutant proteins and transient
transfections, we found that this same region is also re-
quired for PN-mediated HDAC1 depletion; with intermedi-
ate effects being observed when both critical residues
K444 and K476 are mutated and lesser effects being ob-
served when only one site is mutated (Figure 2I). Note
that the HDAC1 D432–482 protein is less abundant than
the other HDAC1 proteins. This is understandable, givenChemistry & Biology 14,that it is a predominantly cytoplasmic protein [28]. Taken
together, these data suggest that PN specifically depletes
HDAC1 protein through ubiquitination and proteasomal
degradation, much as was previously found for HDAC1
depletion following TNF-a treatment [19].
HDAC1 Depletion by PN Leads to p53-Independent
p21 Upregulation and Global Histone Acetylation
The CDKN1A gene, which encodes the cyclin-dependent
kinase inhibitor p21WAF1/CIP1, is one of the few genes that813–823, July 2007 ª2007 Elsevier Ltd All rights reserved 815
Chemistry & Biology
Parthenolide Depletes HDAC1 through ATMFigure 3. PN-Mediated HDAC1 Deple-
tion Upregulates p21WAF1/CIP1 and Acety-
lated Histone H3 Levels through p53-In-
dependent Mechanisms
(A) Quantitative RT-PCR analysis of p21 mRNA
levels in ZR-75-1 cells treated with 15 mM PN.
Error bars indicate standard error of the mean.
(B) Ethidium bromide-stained PCR products
obtained from ZR-75-1 cells treated with 15 mM
PN for 3 hr as indicated, processed by using
the chromatin immunoprecipitation (ChIP)
assay with either the indicated antibodies
(right) or nonimmunogenic control antibodies
and PCR amplified with primers specific for
the p21 proximal promoter. IP, immunoprecip-
itation; Ac-H3, acetylated histone H3.
(C) Western blots of nuclear extract proteins
from ZR-75-1 cells treated with 15 mM PN
and probed with antibodies against total and
acetylated histone H3.
(D) Western blots of whole-cell extract proteins
from normal and p53/ HCT-116 cells treated
with 15 mM PN.are consistently upregulated after cell exposure to pan-
HDAC inhibitors [29]. Similar results have been observed
with cells treated with siRNA against HDAC1 [30]. We
also observed a considerable increase in p21 protein after
PN treatment, which coincided with the disappearance of
HDAC1 (Figures 2A and 2B). This upregulation could be
explained by the substantial increase in p21 mRNA ob-
served after PN treatment, as determined by using real-
time RT-PCR (Figure 3A). This increase in p21 mRNA
most likely resulted from the loss of HDAC1 associated
with the CDKN1A promoter, increased local histone H3
acetylation, and increased transcription of the CDKN1A
gene, as shown in our chromatin immunoprecipitation
(ChIP) assay data (Figure 3B).
Another expected consequence of pan-HDAC inhibition
is an increase in cellular acetylated histone H3 levels [31].
We also observed this after PN treatment of ZR-75-1 cells
(Figure 3C), though not to the same degree as observed
after TNFa treatment [19]. This difference in histone acet-
ylation could reflect differences in global histone acetyl-
transferase activity following each treatment. However,
our findings suggest that specific HDAC1 depletion by
either approach yields a global increase in acetylated
histone H3 levels.
It is well known that theCDKN1A gene is under the con-
trol of the p53 transcription factor and that the ZR-75-1
cells contain wild-type p53 [32]. To test whether p53 is in-
volved with the PN-dependent upregulation of p21, we
tested HDAC1 and p21 responses to PN treatment in
matched p53 wild-type (HCT-116) and deficient (HCT-
116 p53/) cells. We found that PN treatment depleted
HDAC1 protein and caused upregulation of p21 in both
cell lines (Figure 3D). We interpreted these results as indi-
cating that p53 is unnecessary for the specific depletion of
HDAC1 by PN and that the upregulation of p21 by PNdoes
not depend on p53.816 Chemistry & Biology 14, 813–823, July 2007 ª2007 ElsevieHDAC1 Depletion by PN Does Not Require Signal
Transduction through IKK2
PN is known to inhibit IKK2 kinase activity and thereby in-
hibit signaling through NF-kB [21–23]. We have also found
that IKK2 plays a key role in TNFa-dependent HDAC1 de-
pletion [19]. Using wild-type mouse embryo fibroblasts
(MEFs) and MEFs containing homozygous deletions in
IKK2, RelA, and IkBa, we found no evidence that the ab-
senceof theseproteins hadanyeffect onHDAC1depletion
following PN treatment (Figure 4A). These data would
strongly suggest that the IKK/IkBa/NF-kBsignal trans-
ductionpathway is not required for thedepletion ofHDAC1
byPN. Likewise, although PNhas been shown to stimulate
JNK activity [26], absence of JNK1 or JNK2 had no effect
on PN-mediated HDAC1 depletion (Figure 4B). Thus, there
appears to be no absolute requirement for both JNK
proteins for the depletion of HDAC1 protein by PN.
The Phosphoinositide-3-Kinase-like Kinase ATM Is
Required for PN-Mediated HDAC1 Depletion
To elucidate possible signal transduction pathways in-
volved in PN-mediated HDAC1 depletion, cells were
treated with different kinase inhibitors along with PN.
Low concentrations of the kinase inhibitor wortmannin
(Figure 1), which inhibits phosphoinositide-3-kinase
(PI3K), had little effect on PN-mediated HDAC1 depletion
and subsequent p21 upregulation (Figure 5A). However,
high concentrations of wortmannin, which can inhibit sev-
eral phosphoinositide-3-kinase-like kinases (PIKKs) [33],
significantly inhibited PN-mediated depletion of HDAC1
as well as p21 protein accumulation (Figure 5B). In addi-
tion, the more specific PI3K inhibitor LY294002 (Figure 1)
and themammalian Target of Rapamycin (mTOR) inhibitor
rapamycin (Figure 1) had no similar effects on HDAC1 and
p21 (Figure 5B). These data suggested that another PIKK
may be involved in these PN-mediated effects.r Ltd All rights reserved
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Parthenolide Depletes HDAC1 through ATMFigure 4. HDAC1 Depletion Induced by
Treatment with PN Does Not Require In-
tact IKK/IkBa/NF-kB or JNK Signal-
Transduction Pathways
(A) Western blots of nuclear extract proteins
from MEFs with homozygous deletion of
IKK2, RelA, or IkBa genes treated with 15 mM
PN for the indicated times and probed with an-
tibodies against HDAC1 and poly(ADP-ribose)
polymerase (PARP) as indicated (right).
(B)Western blots performed as described in (A)
but with wild-type (wt) and JNK1/ and
JNK2/ MEFs.Three PIKKs-ATM, ataxia-telangiectasia- and Rad3-
related kinase (ATR), and DNA-dependent protein kinase
(DNA-PK) transduce DNA-damage signals to activate
p53 [34–36]. Cells deficient in functional ATR and DNA-
PK did not significantly affect HDAC1 depletion (Figures
5C and 5D). However, cells containing a homozygous
deletion of ATM (ATM/) showed significantly reduced
levels of HDAC1 depletion following treatment with PN
(Figure 5E). Reduced HDAC1 depletion and p21 upregula-
tion after PN treatment could also be observed in a cell line
containing wild-type ATM (ZR-75-1), after treatment with
ATM siRNA (Figure 5F). These data strongly suggest that
ATM is involved in PN-mediated HDAC1 depletion and
its downstream effects.
PN-Mediated Cell Death Occurs through ATM
PN is known to induce apoptosis in many human cancer
cell lines [37]. Several different mechanisms have been
proposed, including (1) redox disruption, (2) endoplasmic
reticulum stress, (3) caspase 8 activation, (4) changes in
proapoptotic Bcl-2 proteins, (5) suppression of NF-kB sig-
naling, and (6) sustained JNK activation. However, the ex-
act contributions of these mechanisms and the pathways
involved remain obscure. To test the involvement of the
NF-kB, JNK, and DNA damage-related PIKK signaling
pathways, cell lines deficient in these different activities
were subjected to PN treatment for 48 hr prior to assaying
their metabolic activity by using the WST-1 cell-prolifera-
tion reagent. MEFs deficient in IKK2, RelA, or IkBa had
essentially the same response to PN as their wild-type
counterpart (Figure 6A). Thus, the IKK/IkBa/NF-kB
signal transduction pathway is not required for PN’s
effects on proliferation and viability of these cells. Nearly
equivalent effects on viability were observed with wild-
type, JNK2/, and JNK1/MEFs following PN treatment
(Figure 6B). Thus, the JNK proteins may also not play
a major role in promoting PN-mediated cell death.
With regards to the PIKKs and PN-mediated cell death,
suppression of ATR activity through the inducible expres-
sion of a dominant-negative mutant protein resulted inChemistry & Biology 14,slightly increased PN sensitivity, especially at low concen-
trations (Figure 6C). These data suggest that wild-type
ATR protein is not required for PN’s cytotoxicity; rather,
ATR may actually be involved in a process that reduces
PN’s cytotoxic effects. DNA-PK, on the other hand, appar-
ently plays no significant role in either process because no
apparent differences were found in the viability of wild-
type and DNA-PK/ cells following PN treatment (Fig-
ure 6D). However, a striking difference in viability was ob-
served between ATM-containing and ATM-deficient cells
following PN treatment, with ATM/ cells exhibiting no
detectable sensitivity to PNwithin the concentration range
tested (Figure 6E). These data would strongly suggest that
PN’s effects on cell proliferation and viability absolutely
require ATM.
One of the prime downstream targets of ATM is p53,
whose activation leads to either cell-cycle arrest or apo-
ptosis through multiple mechanisms [32, 34]. Thus, we
investigated whether p53 is involved in PN-mediated cell
death. MEFs deficient in p53 exhibited only slightly less
sensitivity to PN than their wild-type counterparts at inter-
mediate PN concentrations (Figure 6F). Thus, these data
would suggest that p53 is not the sole mediator of PN
cytotoxicity and that other proteins downstream of ATM
may be involved.
DISCUSSION
Previously, we had found that activation of IKK2 by proin-
flammatory agents caused a specific cellular depletion of
HDAC1 protein levels [19, 38]. Contrary to our expecta-
tions, however, we found in our present studies that the
IKK2-specific inhibitor PN itself promoted HDAC1 deple-
tion. As with treatment with proinflammatory agents
such as TNF-a and interferon-g, the effect of PN was spe-
cific for HDAC1, with the cellular levels and subcellular dis-
tribution of other class I and class II HDACs being unaf-
fected. HDAC1 depletion was observed in many cancer
cell types, as was also previously observed. Likewise,
HDAC1 depletion occurred through ubiquitination and813–823, July 2007 ª2007 Elsevier Ltd All rights reserved 817
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Parthenolide Depletes HDAC1 through ATMFigure 5. PN-Mediated HDAC1 Depletion Requires the PIKK ATM
(A) Western blots of nuclear extract proteins from ZR-75-1 cells treated with 15 mM PN and 1 mM or 20 mM wortmannin (Wort) for 3 hr as indicated.
(B) Western blots of nuclear extract proteins from ZR-75-1 cells treated with 15 mM PN and 1 mM rapamycin (RP) or 10 mM LY294002 (LY) for 3 hr as
indicated.
(C) Western blots of nuclear extract proteins from uninduced GK41-U2OS cells (left panel) containing wild-type ATR (ATR+/+) or doxycycline-induced
GK41-U2OS cells expressing (right panel) a dominant negative mutant of the PIKK ATR (ATR-DN) treated with 15 mM PN.
(D) Western blots of nuclear extract proteins from cells possessing (M059K, left panel) or lacking (M059J, right panel) the PIKK DNA-PK treated with
15 mM PN.
(E) Western blots of nuclear extract proteins from cells possessing (AT22IJE-TpEBS7-YZ5, left panel) or lacking (AT22IJE, right panel) the PIKK ATM
treated with 15 mM PN.
(F)Western blots of nuclear extract proteins fromZR-75-1 cells treatedwith ATM siRNA for 72 hr and 15 mMparthenolide for the final 3 hr, as indicated.proteasomal degradation, and the consequences of PN-
mediated HDAC1 depletion (e.g., loss of HDAC1 associ-
ated with the p21 promoter, increased local and global
histone H3 acetylation, and upregulation of p21 mRNA
and protein) mirrored those observed following TNF-
a treatment. Additionally, as previously seen, these effects
were not dependent on p53. However, unlike our previous
studies with proinflammatory agents, PN-mediated
HDAC1 depletion was unaffected by the absence of
IKK2. Thus, while our present studies suggest a common
mechanism by which HDAC1 protein is depleted, they
also suggest that multiple signaling pathways beyond
those involved in inflammatory responses can promote
HDAC1 depletion. Additionally, our studies indicate that
there may be a hierarchy of HDAC1 responses to different
signaling pathways, whereby HDAC1 depletion promoted
by PN is dominant over any effects on HDAC1 homeosta-818 Chemistry & Biology 14, 813–823, July 2007 ª2007 Elseviesis caused by the inhibition of IKK2-mediated HDAC1
depletion by PN.
The involvement of ATM in the pathway leading from PN
toHDAC1depletionwas rather unexpected. ATM is aPIKK
that serves as a DNA-damage transducer. Normally, it is
activated by double-strand DNA breaks, though there is
evidence that non-DNA damaging agents such as chloro-
quine and other genotoxic stresses such as ROS can also
activate ATM [39, 40]. Since PN is known to increase ROS
levels, it is tempting to conclude that this is themechanism
by which PN activates ATM and thereby induces HDAC1
depletion. However, our preliminary datawith other agents
that modulate ROS levels (e.g., H2O2 and ascorbic acid)
suggest that increasing ROS alone does not cause
HDAC1 depletion (data not shown). Thus, other targets of
PNmustbe involved in thisprocess.Presently, ourworking
hypothesis is that PN chemically modifies a reactiver Ltd All rights reserved
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Parthenolide Depletes HDAC1 through ATMFigure 6. PN Cytotoxicity Requires ATM
(A) Plots of WST-1 viability assays of wild-type (black, squares), IKK2/ (red, triangles), IkBa/ (blue, inverted triangles), and RelA/ (green, dia-
monds) MEFs treated for 48 hr with the PN concentrations indicated. Error bars indicate standard error of the mean.
(B) Plots of WST-1 viability assays of wild-type (black, squares), JNK1/ (red, triangles), and JNK2/ (blue, inverted triangles) MEFs treated for 48 hr
with the PN concentrations indicated. Error bars indicate standard error of the mean.
(C) Plots of WST-1 viability assays of uninduced (black, squares) and doxycycline-induced GK41-U2OS cells (red, triangles) expressing a dominant
negative mutant (ATR-DN) of the PIKK ATR treated for 48 hr with the PN concentrations indicated. Error bars indicate standard error of the mean.
(D) Plots of WST-1 viability assays of human glioma cells possessing (black, squares) and lacking (red, triangles) the PIKK DNA-PK treated for 48 hr
with the PN concentrations indicated. Error bars indicate standard error of the mean.
(E) Plots of WST-1 viability assays of human skin fibroblasts possessing (black, squares) and lacking (red, triangles) the PIKK ATM treated for 48 hr
with the PN concentrations indicated. Error bars indicate standard error of the mean.
(F) Plots ofWST-1 viability assays of wild-type (black, squares) and p53/ (red, triangles) MEFs treated for 48 hr with the PN concentrations indicated.
Error bars indicate standard error of the mean.cysteine residue in a thiol-responsive protein, thereby initi-
ating a signaling cascade leading to ATM activation and
subsequent downstream effects, including ubiquitination
of the lysine-rich C-terminal region of HDAC1, proteaso-
mal degradation of HDAC1, and upregulation of genes
normally repressed by elevated levels of HDAC1 (e.g.,
p21WAF1/CIP1). A schematic outlining this pathway is shown
in Figure 7. Identification of theproteins involved in this sig-Chemistry & Biology 14, 8nal transduction pathway, including the putative sensor
protein and responsible E3 ubiquitin ligases and deubiqui-
tination enzymes, as well as determining the mechanisms
by which PN initiates this process and cells re-establish
HDAC1 homeostasis following PN treatment are several
major undertakings presently underway in our laboratory.
The cytotoxic effects of PN are apparently mediated
through ATM and not through the previously described13–823, July 2007 ª2007 Elsevier Ltd All rights reserved 819
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Parthenolide Depletes HDAC1 through ATMmediators of PN action: IKK2 and JNK [23, 26]. Yet, inhibi-
tion of IKK2 is known to promote apoptosis through the in-
hibition of NF-kB-dependent antiapoptotic gene expres-
sion, sustained JNK activation is known to promote
apoptosis, and a crosstalk exists between these two sig-
naling pathways [41]. It could very well be that there exists
a functional redundancy between individual pathway
members (e.g., JNK1 and JNK2) or entire signaling path-
ways that permits transmission of apoptotic signals
Figure 7. Schematic Representation of the Signal Transduc-
tion Pathway that Leads from PN to HDAC1 Depletion and
p21 Activation
X, unknown sensor protein; Sp1, transcription factor Sp1; H3, histone
H3; E, unknown E3 ubiquitin ligase. HS refers to a free thiol moiety. P,
Ub, and Ac refer to phosphorylated, ubiquitinated, and acetylated pro-
teins, respectively. Dotted lines indicate that multiple steps may be
involved.820 Chemistry & Biology 14, 813–823, July 2007 ª2007 Elsevieprompted by PN. Thus, one can not exclude the possibility
that the IKK/IkBa/NF-kB and JNK signaling pathways
may be involved PN-mediated cytotoxicity, especially for
certain cell types and/or under particular circumstances.
Alternatively, additional proapoptotic signaling pathways
(e.g., p38MAPK) may be involved in PN’s mechanism of ac-
tion, especially in some of the most sensitive cell types
(e.g., Jurkat T cell leukemia cell line). Further studies will
be required to identify the entire kinome responsible for
PN’s cytotoxic effects in different cell types.
The absence of HDAC1 in mice is embryonic lethal, re-
sulting from severe proliferation defects and retardation in
development [7]. This is thought to result from decreased
cyclin-dependent kinase activities and elevated levels of
the cyclin-dependent kinase inhibitors p21WAF1/CIP1 and
p27KIP1. In addition, specific suppression of HDAC1 has
been shown to promote apoptosis in melanoma cells
through a p53-dependent upregulation of the proapop-
totic proteins Bax, Bam, PUMA, and Noxa [42]. While nei-
ther cell-cycle arrest nor p53-dependent apoptosis are
solely indicated in PN-mediated cytotoxicity, HDAC1
has been suggested to transcriptionally regulate several
apoptosis-related genes [30], and suppression of histone
deacetylases in general is well known to induce apoptosis
[4, 6, 8]. Thus, it is interesting to speculate that the cyto-
toxic effects of PN are the direct result of HDAC1 deple-
tion, through both p53-dependent and p53-independent
mechanisms.
HDACi are a new breed of anticancer agents that induce
differentiation, cell-cycle arrest, and apoptosis by upregu-
lation of important cell-cycle regulatory and proapoptotic
genes (e.g., p21, p53, and Bax) by both epigenetic and
posttranslational mechanisms [4, 8]. Despite their impres-
sive therapeutic properties, these inhibitors nonspecifi-
cally inhibit the enzymatic activities of most HDACs and
other proteins with similar catalytic domains and induce
undesirable toxic effects. More preferable would be mole-
cules that target specific HDACs and especially HDAC1,
given its essential role in cell proliferation. Although PN
is not a classic HDACi, its ability to deplete HDAC1 protein
levels through ubiquitination and proteasomal degrada-
tion induces an HDACi-like effect on the p21 gene pro-
moter, namely, increased acetylation of histone H3 and
increased transcription of p21. Such is reminiscent of spe-
cific HDAC1 depletion through short interfering RNAs [30].
Thus, PN may be considered the first example of a small
molecule that specifically inhibits the activity of a single
class I HDAC, HDAC1, throughmodulation of its biological
regulatory pathways. Of course, the inhibition of HDAC1
will ultimately have consequences on the activity of other
HDACs (e.g., HDAC2), as has been previously observed
[30]. However, it is hoped these effects will prove less del-
eterious to patients than sustained, systemic pan-HDAC
inhibition and that molecules like PN will prove useful in
the treatment of chronic diseases such as cancer.
It is increasingly being recognized that many, if not all
cancers, originate from very small populations of pluripo-
tent, self-renewing cancer stem cells (CSCs) [43, 44]. This
follows from observations that large numbers of cancerr Ltd All rights reserved
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most cancers are heterogeneous and not clonal. In addi-
tion, CSCs typically are relatively quiescent, possess
long lifespan, have active DNA repair, and are resistant
to apoptosis [45]. Thus, CSCs are difficult to eliminate
through conventional radiation, hormone, and cytotoxic
chemotherapies and are likely causes of cancer recur-
rence in otherwise successfully treated patients, i.e.,
those exhibiting reductions in tumor mass or leukemic
cell counts. To date, PN is the only small molecule that
has been reported to selectively target CSCs [27]. How
PN is able to accomplish this is unknown, though is
thought to involve both its inhibition of NF-kB activation
and its effects on ROS. In light of our data, it is curious
to speculate that PN’s effects on ATM activation and
HDAC1 depletion may also play a role in its effectiveness
against CSCs, and suggest additional targets that can be
investigated for the development of agents that specifi-
cally target CSCs and lead to a durable cure for cancer.
SIGNIFICANCE
PN is a sesquiterpene lactone and the active ingredi-
ent in feverfew, an herbal remedy for fever, migraines,
arthritis, and superficial inflammation. Its anti-inflam-
matory properties have been shown to result from its
specific inhibition of the signalsome protein IKK2,
which is involved in the proinflammatory signal trans-
duction pathway mediated by the transcription factor
NF-kB. PN has also been shown to disrupt redox reg-
ulation and sustain JNK activation, both leading to cell
death. We have found that PN specifically depletes
cellular levels of HDAC1 protein through a ubiquitina-
tion/proteasomal degradation mechanism that does
not require IKK2 or both JNKs but instead requires
the PIKKATM. Similarly, the cytotoxicity of PNwas de-
pendent on ATM and not members of either the IKK/
IkBa/NF-kB or JNK signaling pathways. Our data
suggests that PN has additional cellular targets than
IKK2, which play a key role in PN’s cytotoxicity. Such
information should prove useful in identifying the
unique mechanisms by which the small molecule PN
specifically targets cancer stem cells, the putative
roots of all cancer. In addition, promoting the biologi-
cal depletion of HDAC1 by PN is a novel approach for
the inhibition of specific HDACs, which offers a new




The ZR-75-1 breast cancer cell line and the transformed human em-
bryonic kidney cell line 293T were obtained from the American Type
Culture Collection (Manassas, VA). HCT-116 and HCT116 p53/ cells
were generated by Bert Vogelstein (The Johns Hopkins University
School of Medicine) and acquired from Peng Huang (our institution).
Wild-type mouse embryo fibroblasts (MEFs) and their complementary
RelA/, IKK2/, and IkBa/ cells were acquired from Paul Chiao
(our institution). MEFs were propagated in Dulbecco’s modifiedChemistry & Biology 14,Eagle’s medium containing 10% fetal bovine serum. AT22IJE-T cells
(ATM/ skin fibroblasts) and ATM protein-expressing (ATM+)
AT22IJE-TpEBS7-YZ5 cells generated by Yossi Shiloh (Tel Aviv Uni-
versity Sackler Faculty of Medicine) as well as DNA-PK/ M059J
and complementary DNA-PK+/+ M059K human glioma cells were ac-
quired from Sai-chin Yeung (our institution). GK41-U2OS human oste-
osarcoma cells, which inducibly express a dominant-negative, Flag
peptide-tagged, kinase-dead ATR protein, were obtained from Paul
Nghiem (Harvard Medical School) and induced by using 1 mg/ml doxy-
cycline 45 hr prior to treatment with PN.
Generally, cells were plated at a density of 106 cells per 10 cm dish
and incubated for 36–48 hr, depending on the cell line used, which re-
sulted in 70%–80% cell confluency in the dishes (23 106 cells). The
medium was replenished before the drugs were added, and the cells
were incubated with the drugs for indicated periods, washed in cold
phosphate-buffered saline, and harvested.
Plasmids, Antibodies, and Drugs
Plasmids capable of expressing C-terminal FLAG epitope-tagged
wild-type and different mutant HDAC1 proteins were obtained from
Ronald DePinho (Dana Farber Cancer Institute). HDAC1, HDAC3,
HDAC4, HDAC6, ATM, paxillin, nonimmunogenic control IgG, and
poly(ADP-ribose) polymerase antibodies were obtained from Santa
Cruz Biotechnology; HDAC2, HDAC8, histone H3, and acetyl histone
H3 antibodies were obtained from Upstate Cell Signaling Solutions;
DNA-PK antibody was obtained from GeneTex; p21 and ubiquitin
antibodies were obtained from Cell Signaling Technology; and FLAG
and b-actin antibodies were obtained from Sigma-Aldrich. Chemicals
PN, wortmannin, and rapamycin were from Sigma-Aldrich; LY294002
was from Cell Signaling Technology.
Western Blotting
Whole-cell, nuclear, and cytoplasmic extracts were prepared as previ-
ously described [19]. Laemmli extracts were prepared by the addition
of 23 sample buffer (125 mM Tris-Cl [pH 6.8], 20% glycerol, 2.5% so-
dium dodecyl sulfate, 10% 2-mercaptoethanol, and 0.005% bromo-
phenol blue) to the cells followed by sonication to shear chromatin.
Typically, 50 mg of each extract was resolved on 10% SDS-PAGE
gels, transferred to nitrocellulose membranes, and blotted with the ap-
propriate antibody. Protein bands were detected by using a SuperSig-
nal chemiluminescence detection kit (Pierce Biotechnology).
Real-Time Reverse-Transcription PCR
RNA extraction and reverse-transcription protocols as well as TaqMan
probe-based quantitative RT-PCR analysis of mRNA were described
previously [19]. The HDAC1, p21, and GAPDH primer-probe mixes
(Taqman Gene Expression Assays, Applied Biosystems) were used
according to the manufacturer’s instructions.
Immunoprecipitation
Nuclei were isolated from ZR-75-1 cells as previously described [19]
and disrupted in RIPA lysis buffer consisting of 50 mM Tris-Cl (pH
7.4), 1% Nonidet P40, 0.25% sodium deoxycholate, 150 mM NaCl,
1 mM ethylenediamine tetraacetic acid, 1 mM NaF, 1 mM phenylme-
thylsulfonyl fluoride, and 1 mg/ml each of leupeptin, pepstatin, and
aprotinin. The lysates were centrifuged to remove chromatin and the
supernatant protein concentration determined using the Bio-Rad
Protein Assay. The supernatants were precleared with a nonimmuno-
genic antibody and protein G-agarose beads (Roche Applied Science)
and then incubated with HDAC1 antibody for 12 hr with continuous
rotation. The antigen-antibody complexes were bound to protein
G-agarose, washed thrice with RIPA buffer, extracted with 23
Laemmli sample buffer, resolved by SDS-PAGE, and western blotted
for HDAC1 and ubiquitin.
Transient Transfection
293T cells were grown to 70% confluency in 100 mm tissue culture
dishes overnight and transfected with 5 mg of plasmid by using the813–823, July 2007 ª2007 Elsevier Ltd All rights reserved 821
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turer’s instructions. After 36 hr, the cells were treated with PN for
3 hr, and nuclear extracts prepared for analysis by western blotting.
HDAC Activity Assay
HDAC activity was determined with an HDAC colorimetric assay kit
(Upstate Cell Signaling Solutions) in 96-well plates. HDAC1 was first
immunoprecipitated as described above. Then the antigen-antibody
complexes bound to protein G-agarose were resuspended in RIPA
buffer and added directly to the assay. Afterwards protein G-agarose
and associated proteins were pelleted following centrifugation at
4,000 3 g for 1 min, and equal volume supernatants were transferred
onto fresh plates, and their absorbance measured. HDAC activity was
plotted relative to the activity present in an untreated control.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed with a ChIP as-
say kit (Upstate Cell Signaling Solutions) as described previously [19].
PCR amplification of the Sp1 binding region (–262 to +31) of the p21
promoter was performed with the primers 21sp-262 (CAGCGCAC
CAACGCAGGCG) and 21sp+31 (CAGCTCCGGCTCCACAAGGA).
The amplified products were run on a 2% agarose gel and stained
with ethidium bromide, and the band densities were determined with
an Alpha Innotech gel analysis system.
siRNA Transfection
Transfection of cells with 20 nM ATM SMARTpool siRNA (Dharmacon)
was performed by using Lipofectamine 2000 Transfection Reagent
(Invitrogen) according to the manufacturer’s instructions. Transfected
cells were incubated for 48 hr before subsequent drug treatment.
Cytotoxicity Assay
Cytotoxicity of PN and its inhibition of cell proliferation were measured
with theWST-1 assay reagent (Roche Applied Science). The cells were
seeded in 24-well plates at a concentration of 10,000 cells/well in
500 ml of medium and incubated for 12 hr. Drugs at indicated concen-
trations were added to the wells, and the cells were incubated for an
additional 48 hr. Following the manufacturer’s instructions, WST-1
reagent was added to the cells, and after appropriate incubation, the
absorbance was measured. The absorbance data were plotted as
the percent change of absorbance against the concentration of the
drug.
Supplemental Data
Supplemental Data include one figure that is available online at http://
www.chembiol.com/cgi/content/full/14/7/813/DC1/.
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